Pharma company Piramal Healthcare today said it is looking for acquisitions in the fields of patented drugs, contract research and research molecules and will raise Rs 1,000 crore for this purpose.
The company's board had recently approved raising of Rs 1,000 crore for this purpose within six to eight months, Piramal Healthcare Director Swati Piramal told reporters on the sidelines of an Assocham meeting here.
But "how to raise it is yet to be decided," she added.
Piramal had last month said the company was looking at acquisitions overseas.
"Many global pharma companies are on our radar. We are looking for a cross-border acquisition. But we have not finalised anything so far," she had said.
The company, which had also entered the pathological testing business, has 100 pathlabs across the country.
But the firm does not have plans to enter the hospitals business, she said, adding that the direct tax code was thwarting setting up of new plants in backward regions.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
